Dyve Biosciences is pioneering a transdermal delivery technology known as the DMAX platform, which enables the effective delivery of pH-modulating agents and other therapeutic molecules that are typically unsuitable for oral or injectable administration. This innovative platform utilizes a proprietary emulsion technology that temporarily alters the skin's lipid matrix, allowing for the non-invasive delivery of drugs while enhancing their pharmacokinetics. By targeting the acidic microenvironments associated with various diseases, particularly in oncology and immunology, Dyve aims to improve treatment outcomes by neutralizing these conditions, which are known to contribute to disease progression and therapeutic resistance.

The company's lead products, DYV800 and DYV702, exemplify the application of this technology. DYV800 is designed to raise the pH of acidic tumor microenvironments, potentially inhibiting tumor growth and enhancing the effectiveness of existing therapies. Meanwhile, DYV702 has shown promising results in clinical trials for alleviating pain associated with acute gouty arthritis, demonstrating significant improvements in pain resolution and physical function. Dyve's approach not only addresses the limitations of traditional drug delivery methods but also opens new avenues for treating a range of conditions by leveraging the skin as a viable route for systemic drug delivery.

United States

At Dyve Biosciences, we leverage our proprietary transdermal platform to deliver intuitive, targeted pH modulation to treat a range of immunologic and oncologic diseases. By directly targeting the acidic microenvironments that drive cancer cell growth and inflammation, we are taking decades of proven science from the petri dish to the patient.

Dyve Biosciences

Company Details